Scope Cleaning Without Scope Removal

Modern surgery is becoming more high-tech but faces a persistent low-tech challenge... VISIBILITY.

Bayou Surgical's troCarWash™️ brings a transformative solution to minimally invasive surgery (MIS) with its pioneering automated visualization system.

  • Enhanced Vision
  • Better Procedure Continuity
  • Operative Cost Efficiency
  • Seamless Lens Cleaning

Investment Opportunity - Series B: $10M First Revenues Expected in 6 Months

This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.

Investor Deck for Review
Interested in Learning More

DISCLAIMER:

CONFIDENTIAL – NOT FOR GENERAL DISTRIBUTION. Bayou Surgical (the “Company”) has limited operating history. Certain information herein is made on a forward-looking basis. Any references to projected returns, investment opportunities or strategies are only guidelines and are not intended to supersede the investment strategy described in the Company’s Offering Documents (as defined herein). We make no warranty or representation, whether express or implied, for the accuracy, completeness or usefulness of any information disclosed. By accepting this document and/or attachments, you agree that you or the entity that you represent meets all investor qualifications. Please see important disclaimers at the bottom of this page.

Demonstration Lens Cleaning Without Scope Removal: Reduce Surgery Disruption

Lens Cleaning Disrupts Surgery and Increases Risk

Da Vinci Robotic Lens Cleaning

Takes 60 seconds per cleaning event. Adds over $62 per minute to procedure costs.

Da Vinci is a registered trademark of Intuitive Surgical

Laparoscopic Lens Cleaning

Requires 30-60 seconds per cleaning, with risks of fogging or contamination upon reinsertion.

Bayou troCarWash Advantage

Cleans in less than 1 second with no need to remove the scope. Cleans in less

Poor Vision During MIS Surgery is Costly and Unsafe

Metrics
Laparoscopic Surgery 3
Robotic Surgery 2
Surgery with impaired vision
37% 3
53%
Lens contamination events
82% require withdrawal 4
93% require cleaning
Cleaning time per procedure
11 min 3
6.4 min
Contamination events/hour
7.5 3
5.8
Procedure delay
6.5% 5
4.3%
Cleaning cost per procedure
$708 1
$846 1

See important footnotes at the bottom of this page.

Hospital Economics: How troCarWash Saves Time and Money 1-5

troCarWash
Laparoscopy
Robotic
Removal Rate for cleaning
6.6%
4.3%
Average time per procedure (min)
160
160
Cost of operating theatre per minute
$67
$123
Per procedure savings
$708
$846
Number of MIS Cases per year
1200
1200
Total Hospital Savings per year
$849,024
$1,015,488

See important footnotes at the bottom of this page.

Market Size and Growth Projection

Laparoscopy

Cases/Yr
Addressable Market
World Wide
15M
$4.5B
USA
4.9M
$1,47B

Robotic- Intuitive Surgical

Cases/Yr
Addressable Market
World Wide
2.3M
$747M
USA
0.8M
$260M

The Ask & Use of Proceeds

Series B: $10M

  • Build reference sites at 10mm scale
  • Expand sales to targeted procedures
  • Complete and launch robotic SKU
  • Complete and launch 5mm laparoscopic SKU
  • Establish a small sales team to achieve $5M+ in sales
  • Strengthen partnerships with robotic surgical platforms
  • Develop a next-generation plug-and-play model
  • Enhance and expand intellectual property
  • Achieve cash flow positivity
  • Last round of capital needed

This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.

The Future of Surgical Innovation

Join us in shaping the future of surgical care and innovation. We are excited to share our journey and explore how we can collaborate to make groundbreaking advancements in medical technology. For any inquiries or partnership opportunities, feel free to connect with Sharad Joshi, our Chief Executive Officer, who is dedicated to working together and realizing a shared vision for improved patient outcomes and healthcare excellence.

Interested in Learning More

FOOTNOTES:

  1. A financial analysis of operating room charges for robotic-assisted gynecologic surgery, Journal of Turk Ger Gynecology Association, Burak Zeybek, et al.
  2. Impaired robotic surgical visualization: archaic issues in a modern operating room, Journal of Robotic Surgery (2023) 17:2875-2880, Nethra Venkatayogi, et al
  3. Impact of Laparoscopic Lens Contamination in Operating Theatres: A study in the Frequency and Duration of Lens Contamination and Commonly Utilized Techniques to Maintain a Clear Vision. Surgical Laparoscopy. Vol 26, no 4, August 2016, Yong, N Grange, et al.
  4. Quantifying Intraoperative Laparoscopic Visual Field Opacity. JSLS 2017; Vol 21: issue 2, 1-7, Abbit D Khallouq BB, et al.
  5. A quantitative study of disruption in the operating room during laparoscopic antireflux surgery. Surg Endosc; 22:2171-2177, July 2008
  6. Research & Markets: https://www.globenewswire.com/newsrelease/2018/09/19/1572863/0/en/Global-Laparoscopy-and-Endoscopy-Devices-Market-2025-Focus-on-Surgical-Procedures-Cholecystectomy-and-Hysterectomy-and-Product-Types-Arthroscopes-Neuroendoscopes-Cystoscope-and-Bro.html.

7. Intuitive Surgical Annual Report

8. Outcomes of Total Laparoscopic Hysterectomy Using 5mm vs. 10mm Laparoscope, Journal of Minimally

DISCLAIMERS:

CONFIDENTIAL – NOT FOR GENERAL DISTRIBUTION. This document shall not be copied, reproduced, or distributed to any other person at any time (other than to any of the recipient’s legal, tax and accounting advisors who agree to abide by these limitations) without the express written permission of Bayou Surgical (the “Company”) in each instance. This document is designed for accredited investors only, each of whom should consult with their own financial, legal, accounting, tax or other advisors as appropriate. By accepting this document, the recipient agrees to keep the information contained herein confidential and warrants that the recipient or the entity represented thereby meets all investor qualifications.

RISK OF LOSS. The Company has limited operating history. An investment in the Company involves significant risk, including the risk of losing all or a portion of an investment. Investors will be required to bear the financial risks of their investment in the Company for an indefinite period of time, irrespective of any material adverse changes in the Company, the financial markets, the Company’s strategy, such investors’ financial status and/or liquidity requirements. There can be no assurance that the Company’s objectives will be achieved and a return realized. No representation is being made that the Company will or is likely to achieve any specific performance targets. Any performance information depicted herein is not indicative of future results.

ACCURACY OF INFORMATION. The information contained in this document is from sources the Company believes to be accurate. Certain information in this report may have been obtained from third parties. The Company, its affiliates and third party providers make no warranty or representation, whether express or implied, for the accuracy, completeness or usefulness of any information disclosed. Neither the Company nor any of its affiliates shall be held liable for any errors or omissions related to the information provided in this document.

NOT AN INVESTMENT RECOMMENDATION OR ADVICE. The information in this document is presented exclusively to Company prospects for due diligence and informational purposes only and should in no way be considered a research report, a recommendation, or personalized investment advice of any kind. This document does not constitute investment, legal, or tax advice or an offer to sell, or a solicitation of an offer to buy, securities, or an endorsement with respect to the Company or for any investment strategy or vehicle. Any such offer will be made only by means of a stock purchase agreement and other relevant offering documents of the Company, each in their final form, and will be subject to the terms and conditions contained therein (together, the “Offering Documents”). Any references to projected returns, investment opportunities or strategies are only guidelines and are not intended to supersede the strategy described in the Company’s Offering Documents (as defined herein). Before considering any investment, eligible investors in applicable jurisdictions should carefully review the Company 's Offering Documents, including a complete description of the Company and its business, strategies, and risks.

FORWARD LOOKING STATEMENTS. Certain statements included in this document, including, without limitation, statements regarding the Company’s goals, its strategy, and statements as to the Company’s beliefs, expectations or opinions are forward-looking statements within the meaning of the relevant securities laws and are subject to numerous known and unknown risks and uncertainties. Forward-looking statements generally include the use of words such as "believes," "intends," "expects," "anticipated," "plans," and similar expressions. Undue reliance should not be placed on these forward-looking statements. Actual results could differ materially from those expressed or implied in the forward-looking statements for many reasons, including the risks described herein and in the Company’s Offering Documents. Such statements relate only to events as of the date on which the statements are made and there can be no assurance that future results, levels of activity, performance, or actual achievements of the Company will meet these expectations. Actual results may materially differ from any hypothetical data as presented herein, including any hypothetical financial projections prepared by the Company.

ANY INVESTMENT IN THE COMPANY REPRESENTS A SPECULATIVE INVESTMENT, INVOLVES A HIGH DEGREE OF RISK, AND MAY RESULT IN A TOTAL LOSS OF INVESTMENT